Evidence-Based Management of Cancer in the Elderly

Hamerman D. Toward an understanding of frailty. Ann Intern Med. 1999; 130: 945–950.

Cassel C.K. Money, medicine, and Methuselah. Mt Sinai J Med. 1998; 65: 237–245.

Duthie E.H. Physiology of aging: relevance to symptoms, perceptions, and treatment tolerance. In: Balducci L. , Lyman G.H. , Ershler W.B. , eds. Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood Academic Publ; 1998: 247–262.

Extermann M. , Overcash J. , Lyman G.H. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998; 16: 1582–1587.

Balducci L. , Stanta G. Cancer in the frail patient: a coming epidemic. Hematol Oncol Clin North Am. 2000; 14: 235–250. Review.

Reuben D.B. , Rubenstein L.V. , Hirsch S.H. Value of functional status as predictor of mortality: results of a prospective study. Am J Med. 1992; 93: 663–669.

Manton K.G. A longitudinal study of functional change and mortality in the United States. J Gerontol. 1988; 43: S153–S161.

Inouye S.K. , Peduzzi P.N. , Robison J.T. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA. 1998; 279: 1187–1193.

Satariano W.A. , Ragland D.R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994; 120: 104–110.

Piccirillo J.F. Inclusion of comorbidity in a staging system for head and neck cancer. Oncology (Huntingt). 1995; 831–836; discussion 841,845–848.

Newschaffer C.J. , Bush T.L. , Penberthy L.E. Does comorbid disease interact with cancer? An epidemiological analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol A Biol Sci Med Sci. 1998; 53A: M372–378.

Extermann M. Assessment of the older cancer patient. Hematol Oncol Clin North Am. 2000; 14: 63–77.

Eagles J.M. , Beattie J.A.G. , Restall D.B. Relationship between cognitive impairment and early a death in the elderly. Br Med J. 1990; 300: 239–240.

Flacker J.M. , Kiely D.K. A practical approach to identifying mortality-related factors in established long-term care residents. J Am Geriatr Soc. 1998; 46: 1012–1015.

Winograd C.H. , Gerety M.B. , Chung M. Screening for frailty: criteria and predictors of outcomes. J Am Geriatr Soc. 1991; 39: 778–784.

Covinsky K.E. , Kahana E. , Chin M.H. Depressive symptoms and 3-year mortality in older hospitalized medical patients. Ann Intern Med. 1999; 130: 563–569.

Tinetti M.E. , Williams C.S. The effect of falls and fall injuries on functioning in community-dwelling older persons. J Gerontol A Biol Sci Med Sci. 1998; 53: M112–M119.

Inouye S.K. , Bogardus S.T. Jr , Charpentier P.A. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999; 340: 669–676.

Rockwood K. , Stadnyk K. , Macknight C. A brief clinical instrument to classify frailty in elderly people. Lancet. 1999; 353: 205–206.

Mendonca J.D. , Velamoor V.R. , Sauve D. Key features of maltreatment of the infirm elderly in home settings. Can J Psychiatry. 1996; 41: 107–113.

Balducci L. , Extermann M. Cancer and aging: an evolving panorama. Hematol Oncol Clin North Am. 2000; 14: 1–16.

Narain P. , Rubenstein L.Z. , Wieland G.D. Predictors of immediate and 6-month outcome in hospitalized elderly patients: the importance of functional status. J Am Geriatr Soc. 1988; 36: 775–783.

Barberger-Gateau P. , Fabrigoule C. , Helmer C. Functional impairment in instrumental activities of daily living: an early clinical sign of dementia? J Am Geriatr Soc. 1999; 47: 456–462.

Monfardini S. , Ferrucci L. , Fratino L. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer. 1996; 77: 395–401.

Paolisso G. , Tagliamonte M.R. , Rizzo M.R. Oxidative stress and advancing age: results in healthy centenarians. J Am Geriatr Soc. 1998; 46: 833–838.

Stanta G. Morbid anatomy of aging. In: Balducci L. , Lyman G.H. , Ershler W.B. , eds. Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood Academic Publ; 1998: 229–235.

Cova D. , Beretta G. , Balducci L. Cancer chemotherapy in the older person. In: Balducci L. , Lyman G.H. , Ershler W.B. , eds. Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood Academic Publ; 1998: 429–442.

Jitapunkul S. , Harwood R. Plasma osmolality and survival of elderly continuing-care patients. Age Ageing. 1990; 19: 346–347.

Rink L. , Cakman I. , Kirchner H. Altered cytokine production in the elderly. Mech Ageing Dev. 1998; 102: 199–209.

Hack V. , Breitkreutz R. , Kinscherf R. The redox state as a correlate of senescence and wasting and as a target for therapeutic intervention. Blood. 1998; 59–67.

Jette A.M. , Jette D.U. , Ng J. Are performance-based measures sufficiently reliable for use in multicenter trials? J Gerontol A Biol Sci Med Sci. 1999; 54: M3–6.

Extermann M. Acute leukemia in the elderly. Clin Geriatr Med. 1997; 13: 227–244.

Buchner T. Treatment of acute myeloid leukemia in the older patient. In: Balducci L. , Lyman G.H. , Ershler W.B. , eds. Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood Academic Publ; 1998: 545–550.

O'Reilly S.E. , Connors J.M. , Macpherson N. Malignant lymphomas in the elderly. Clin Geriatr Med. 1997; 13: 251–264.

Thigpen J.T. Ovarian cancer in the older patient. In: Balducci L. , Lyman G.H. , Ershler W.B. , eds. Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood Academic Publ; 1998: 721–732.

Willman C.L. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol. 1997; 34(suppl 5): 25–33.

Preti H.A. , Cabanillas F. , Talpaz M. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med. 1997; 127: 186–194.

Balducci L. , Silliman R.A. , Baekey P. Breast cancer: an oncologic perspective. In: Balducci L. , Lyman G.H. , Ershler W.B. , eds. Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood Academic Publ; 1998: 629–660.

Antonia S.J. , Robinson L.A. , Ruckdeschel J.C. Lung cancer. In: Balducci L. , Lyman G.H. , Ershler W.B. , eds. Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood Academic Publ; 1998, 610–628.

Newcomb P.A. , Carbone P.P. Cancer treatment and age: patient perspectives. J Natl Cancer Inst. 1993; 85: 1580–1584.

Christman K. , Muss H.B. , Case L.D. Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association experience. JAMA. 1992; 268: 57–62.

Ibrahim N. , Buzdar A. , Frye D. Should age be a determinant factor in treating breast cancer patients with combination chemotherapy? Proc Annu Meet Am Soc Clin Oncol. 1993; 12: 68.

Giovanazzi-Bannon S. , Rademaker A. , Lai G. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1994; 12: 2447–2452.

Gelman R.S. , Taylor SG 4th . Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 year old with advanced breast cancer: the elimination of age trend in toxicity by using doses based on creatinine clearance. J Clin Oncol. 1984; 2: 1404–1413.

Balducci L. Special problems in the management of older persons with cancer. ASCO educational booklet; 1999.

Stein B.N. , Petrelli N.J. , Douglass H.O. Age and sex are independent predictors of 5-fluorouracil toxicity: analysis of a large scale phase III trial. Cancer. 1995; 75: 11–17.

Zinzani P.L. , Storti S. , Zaccaria A. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen. Experience on 350 patients. Blood. 1999; 94: 33–38.

Gomez H. , Mas L. , Casanova L. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematological toxicity. J Clin Oncol. 1998; 16: 2352–2358.

Armitage J.O. , Potter J.F. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc. 1984; 32: 269–273.

Balducci L. Corcoran MB. Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am. 2000; 14: 193–212.

Gurney H. Dose calculation of anticancer drugs: a review of current practice and introduction of an alternative. J Clin Oncol. 1996; 14: 2590–2611.

Borkowski J.M. , Duerr M. , Donehower R.C. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol. 1994; 33: 493–496.

Bastion Y. , Blay J.Y. , Divine M. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival: a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997; 15: 2945–2953.

Sonneveld P. , de Ridder M. , van der Lelie H. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP vs CNOP chemotherapy. J Clin Oncol. 1995; 13: 2530–2539.

Tirelli U. , Errante D. , Van Glabbeke M. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998; 16: 27–34.

Silber J.H. , Fridman M. , DiPaola R.S. First-cycle blood counts and subsequent neutropenia, dose reduction or delay in early-stage breast cancer therapy. J Clin Oncol. 1998; 16: 2392–2400.

Ratain M.J. , Schilsky R.L. , Choi K.E. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther. 1989; 45: 226–233.

Pierelli L. , Perillo A. , Greggi S. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel and cisplatin combination chemotherapy: results of a randomized comparison. J Clin Oncol. 1999; 17: 1288–1296.

Gabrilove J.L. , Einhorn L.H. , Livingston R.B. Once weekly dosing of epoetin alfa is similar to three-times weekly dosing in increasing hemoglobin and quality of life. Proc Annu Meet Am Soc Clin Oncol. 1999; 18: A574.

Glaspy J. , Bukowski R. , Steinberg D. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997; 15: 1218–1234.

Demetri G.D. , Kris M. , Wade J. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998; 16: 3412–3425.

Reuben D.B. , Frank J.C. , Hirsch S.H. A randomized clinical trial of outpatient geriatric assessment (CGA), coupled with an intervention, to increase adherence to recommendations. J Am Geriatr Soc. 1999; 47: 269–276.

Tinetti M.E. , Baker D.I. , McAvay G. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med. 1994; 331: 821–827.